GKOS

Glaukos Corporation

$176.85

+1.97% Oct 21 close

Health CareS&P 600 Compare

1M 3M 6M 1Y 2Y

GKOSSPY

+5.3%

+9.5%

+15.7%

+45.4%

YTD

+56.6%

+133.1%

Live chart

Loading live chart…

What they do

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.

Healthcare · Medical Devices

For information only · Important disclosures

Grades vs sector

Momentum

93rd percentile in sector

12-1 return: +86.4%
Percentile within its GICS sector across the S&P 1500.

Growth

95th percentile in sector

A+

Revenue growth (YoY): +49.5%
Percentile within its GICS sector across the S&P 1500.

Value

1st percentile in sector

Forward E/P: 0.3% · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.

Profitability

7th percentile in sector

Profit margin: -30.7% · Return on equity: -26.0%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Zacks · Oct 21

Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales

Zacks · Oct 21

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

Zacks · Oct 21

iShares Russell 2000 Growth (IWO) Sells Moog and BrightSpring on Friday

GuruFocus.com · Oct 20

iShares Russell 2000 Index Fund (IWM) Adds BrightSpring Health and Moog on Oct. 14

GuruFocus.com · Oct 16

Key stats

Market value$10.4B

P/E (next 12 months, estimated)338.3

52-week range$73.16 – $191.62

Revenue growth (latest quarter vs a year ago)+49.5%

Dividend yieldNo dividend

Analyst consensusStrong Buy (13)

Average analyst price target$199.31 (+13%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score -2 (DCF counts double).

▼Forward P/E vs sector338.3x vs median 17.6x

▼Piotroski F-score2/9

▲Altman Z25.3 (safe)

•Analyst target+13% (13 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.69 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6× · 99th pct

338.3×
pricier

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1× · 94th pct

17.0×
pricier

Price / book

sector median 3.5× · 92nd pct

15.3×
pricier

FCF yield

sector median 4.1% · 11th pct

-0.1%
pricier

Forward EPS $0.52 vs trailing $-3.26. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

60.7%

Operating margin

-31.6%

FCF margin

-2.0%

Net margin

-30.7%

Return on equity

-27.6%

Return on invested capital

-26.6%

Net debt / EBITDA

–

Current ratio

5.0×

Interest cover

-39.4×

Cash conversion (OCF/NI)

–

Piotroski F-score 2/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 25.3 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$199

+13%

Analysts

Strong Buy

Range

$172–$225

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$507.4M	$-187.7M	$-22.5M
2024	$383.5M	$-146.4M	$-67.6M
2023	$314.7M	$-134.7M	$-78.0M
2022	$282.9M	$-99.2M	$-63.3M
2021	$294.0M	$-49.6M	$-23.1M
2020	$225.0M	$-120.3M	$-29.9M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +21.5%.

Earnings

Next report: 2026-10-28 · after close · EPS est -0.09

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-29	-0.21	-0.14	+33.5%
2026-04-29	-0.28	-0.18	+35.9%
2026-02-17	-0.20	-0.28	-43.2%
2025-10-29	-0.26	-0.16	+38.9%
2025-07-30	-0.26	-0.24	+7.0%
2025-04-30	-0.35	-0.22	+36.3%
2025-02-20	-0.39	-0.40	-3.0%
2024-11-04	-0.48	-0.28	+41.4%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$185.6M	+49.5%
2026-03-31	$150.6M	–
2025-12-31	$143.1M	–
2025-09-30	$133.5M	–
2025-06-30	$124.1M	–

Analyst actions

BTIG

2026-10-12 · main

Buy → Buy
PT $205

Jefferies

2026-09-22 · main

Buy → Buy
PT $210

BTIG

2026-08-20 · main

Buy → Buy
PT $202

UBS

2026-07-30 · main

Neutral → Neutral
PT $172

HC Wainwright & Co.

2026-07-30 · main

Buy → Buy
PT $195

Citigroup

2026-07-30 · main

Buy → Buy
PT $188

Insider trades

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-10-05

Sell
$51.7K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-10-05

Sell
$53.9K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-10-05

Sell
$145.6K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-09-25

Sell
$167.7K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-09-25

Sell
$35.3K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-09-25

Sell
$20.8K

Navratil Tomas

CHIEF DEVELOPMENT OFFICER · 2026-09-25

Sell
$25.3K

Navratil Tomas